Positive News SentimentPositive NewsNASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Price, News & Analysis $1.49 -0.03 (-1.97%) Closing price 04:00 PM EasternExtended Trading$1.49 0.00 (0.00%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Acrivon Therapeutics Stock (NASDAQ:ACRV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acrivon Therapeutics alerts:Sign Up Key Stats Today's Range$1.48▼$1.5750-Day Range$1.38▼$2.0952-Week Range$1.15▼$3.56Volume318,106 shsAverage Volume365,945 shsMarket Capitalization$63.77 millionP/E RatioN/ADividend YieldN/APrice Target$11.67Consensus RatingModerate Buy Company Overview Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics. The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials. In parallel, Acrivon is advancing additional stapled-peptide programs directed at other oncogenic KRAS mutants such as G12D, with the goal of expanding its pipeline to address multiple unmet needs in solid tumor oncology. Acrivon was established in 2021 as a spin-out from Calibr, the drug discovery division of The Scripps Research Institute, and is headquartered in Redwood City, California. The company leverages its origin in academic research to maintain close collaborations with leading cancer centers and translational science groups across North America and Europe. Supported by a management team with extensive experience in biotechnology and pharmaceutical drug development, Acrivon is building strategic partnerships and advancing its peptide platform to potentially deliver first-in-class or best-in-class therapies for patients with RAS-mutant cancers. The company continues to focus on rigorous clinical development and regulatory engagement to bring novel peptide-based oncology treatments to market.AI Generated. May Contain Errors. Read More Acrivon Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreACRV MarketRank™: Acrivon Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 487th out of 855 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingAcrivon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAcrivon Therapeutics has a consensus price target of $11.67, representing about 683.0% upside from its current price of $1.49.Amount of Analyst CoverageAcrivon Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Acrivon Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($1.89) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acrivon Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acrivon Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcrivon Therapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Acrivon Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.15% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 6.07.Change versus previous monthShort interest in Acrivon Therapeutics has recently increased by 12.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News SentimentAcrivon Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.Search Interest8 people have searched for ACRV on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows3 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.50% of the stock of Acrivon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acrivon Therapeutics' insider trading history. Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACRV Stock News HeadlinesAcrivon Therapeutics IncMay 25, 2026 | money.usnews.comAcrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation SummitMay 21, 2026 | markets.businessinsider.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.June 16 at 1:00 AM | Behind the Markets (Ad)Acrivon Therapeutics CEO to Participate in Virtual Fireside Chat at TD Cowen’s 7th Annual Oncology Innovation SummitMay 21, 2026 | quiverquant.comQAcrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation SummitMay 21, 2026 | globenewswire.comAcrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 15, 2026 | globenewswire.comAcrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical CatalystsMay 13, 2026 | globenewswire.comAcrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads ...April 18, 2026 | markets.businessinsider.comSee More Headlines ACRV Stock Analysis - Frequently Asked Questions How have ACRV shares performed this year? Acrivon Therapeutics' stock was trading at $2.41 at the beginning of 2026. Since then, ACRV stock has decreased by 38.2% and is now trading at $1.49. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) issued its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.49) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.49). When did Acrivon Therapeutics IPO? Acrivon Therapeutics (ACRV) raised $100 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO. Who are Acrivon Therapeutics' major shareholders? Top institutional investors of Acrivon Therapeutics include Renaissance Technologies LLC (1.77%). Insiders that own company stock include Ltd Chione, Perceptive Advisors Llc, Peter Blume-Jensen, Eric Devroe and Adam D Levy. View institutional ownership trends. How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acrivon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acrivon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), ServiceNow (NOW) and Adobe (ADBE). Company Calendar Last Earnings5/13/2026Today6/16/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 3 weeks, ACRV's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACRV CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Price Target for Acrivon Therapeutics$11.67 High Price Target$19.00 Low Price Target$8.00 Potential Upside/Downside+683.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.90 million Net MarginsN/A Pretax MarginN/A Return on Equity-64.43% Return on Assets-57.08% Debt Debt-to-Equity RatioN/A Current Ratio8.98 Quick Ratio8.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.57 per share Price / Book0.42Miscellaneous Outstanding Shares42,800,000Free Float38,308,000Market Cap$63.77 million OptionableNot Optionable Beta1.89 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ACRV) was last updated on 6/16/2026 by MarketBeat.com Staff. From Our PartnersDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredA 3M Oz. Historical Gold Resource And A Market That Hasn't Caught UpOne Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a d...Wall Street Logic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
